Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
talabostat + gemcitabine
- Development stage
- Phase 2
- Lead developer
- Biodexa Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral (talabostat), Intravenous (gemcitabine)
01
Overview
Talabostat + gemcitabine is a **combination therapy** composed of two agents: - **Talabostat** is an orally administered small molecule inhibitor of dipeptidyl peptidases, including fibroblast activation protein (FAP), DPP8, DPP9, and DPPIV. By inhibiting FAP and related enzymes highly expressed in certain tumors, talabostat remodels the tumor microenvironment, upregulates cytokines and chemokines, activates T-cell and NK-cell responses, and potentially reverses tumor-induced immunosuppression. - **Gemcitabine** is a nucleoside analog and chemotherapeutic agent that is incorporated into DNA during replication, causing chain termination, blockade of DNA synthesis, and apoptosis in rapidly dividing tumor cells. The combination has been specifically investigated in **metastatic pancreatic cancer**, with Phase 2 clinical trials showing some encouraging response rates and survival outcomes[1][4]. Preclinical studies indicate that talabostat may sensitize tumors to cytotoxic agents like gemcitabine by targeting the tumor stroma and immune evasion pathways[1][4].
- Other names
- talabostatVal-boroProGemzar
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)DPP8 (Dipeptidyl peptidase 8)DPP9 (Dipeptidyl Peptidase 9)FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on talabostat + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on talabostat + gemcitabine.